Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Egypt pharma market performance ws-04.10

7,940 views

Published on

The Egyptian Pharmaceutical market performance 03.10

Published in: Health & Medicine

Egypt pharma market performance ws-04.10

  1. 1. EGYPT PHARMA marketperformancePrepared by: Walid SaafanApril 2010
  2. 2. Leading corporate performance 03/10 YTD-03/10 MAT-03/10 Value. Inc.Sales GR% MS%. MS G/L Ev.Index Value. Inc.sales GR%. MS%. MS G/L Ev.Index Value. Inc.Sales GR%. MS%. MS G/L Ev.IndexTotal Market 1,333.4 15.0% 3,904.8 15.9% 15,459.1 18.9%GLAXOSMITHKLINE* 127.2 28.3 1 28.6% 6 9.54% 1.01% 111.8% 316.9 40.9 1 14.8% 14 8.11% -0.07% 99.1% 1,396.7 470.3 1 50.8% 2 9.03% 1.91% 126.8%PHARCO* 92.8 12.8 2 15.9% 10 6.96% 0.06% 100.8% 295.7 38.6 3 15.0% 13 7.57% -0.06% 99.2% 1,114.9 136.4 3 13.9% 18 7.21% -0.31% 95.8%NOVARTIS 92.2 12.4 3 15.5% 11 6.91% 0.03% 100.4% 272.6 38.9 2 16.6% 10 6.98% 0.05% 100.7% 1,091.0 177.0 2 19.4% 11 7.06% 0.03% 100.4%EIPICO* 70.1 2.8 12 4.2% 19 5.25% -0.55% 90.6% 223.0 28.7 5 14.7% 15 5.71% -0.06% 99.0% 857.4 124.4 6 17.0% 14 5.55% -0.09% 98.4%SANOFI AVENTIS* 69.8 2.9 11 4.3% 18 5.24% -0.54% 90.7% 219.2 25.5 6 13.1% 16 5.61% -0.14% 97.6% 870.5 135.9 4 18.5% 12 5.63% -0.02% 99.7%AMOUN PHARM.CO. 57.8 8.6 4 17.6% 8 4.33% 0.09% 102.2% 169.7 37.5 4 28.4% 6 4.35% 0.42% 110.8% 657.4 102.6 7 18.5% 13 4.25% -0.01% 99.7%PFIZER* 50.3 1.8 17 3.7% 20 3.78% -0.41% 90.2% 150.5 5.8 17 4.0% 21 3.85% -0.44% 89.8% 624.8 22.0 21 3.6% 22 4.04% -0.59% 87.2%EVA PHARMA 40.1 8.5 5 27.0% 7 3.01% 0.28% 110.4% 100.7 18.2 10 22.0% 9 2.58% 0.13% 105.3% 376.7 81.6 9 27.7% 7 2.44% 0.17% 107.4%SIGMA* 34.1 2.4 13 7.5% 14 2.56% -0.18% 93.5% 99.3 18.3 9 22.5% 8 2.54% 0.14% 105.7% 382.9 90.4 8 30.9% 6 2.48% 0.23% 110.1%SERVIER* 33.2 2.3 16 7.3% 15 2.49% -0.18% 93.3% 101.0 9.0 15 9.8% 18 2.59% -0.14% 94.8% 394.6 44.5 13 12.7% 19 2.55% -0.14% 94.8%MEDICAL UNION PHA* 29.5 1.0 20 3.5% 21 2.21% -0.25% 90.0% 82.5 5.2 19 6.7% 20 2.11% -0.18% 92.1% 331.9 46.6 12 16.3% 15 2.15% -0.05% 97.9%ADWIA* 21.9 7.5 7 51.9% 3 1.64% 0.40% 132.1% 61.9 19.8 7 47.1% 3 1.59% 0.34% 127.0% 230.1 125.6 5 120.1% 1 1.49% 0.68% 185.2%MULTIAPEX PHARM. 21.4 5.8 9 37.6% 4 1.60% 0.26% 119.6% 60.4 15.8 12 35.5% 4 1.55% 0.22% 116.9% 224.9 56.1 11 33.3% 5 1.45% 0.16% 112.1%MERCK SERONO 20.8 2.3 14 12.3% 12 1.56% -0.04% 97.6% 61.8 13.3 13 27.4% 7 1.58% 0.14% 110.0% 239.2 68.8 10 40.4% 3 1.55% 0.24% 118.1%SEDICO 20.4 1.1 19 5.5% 16 1.53% -0.14% 91.7% 55.8 4.5 20 8.9% 19 1.43% -0.09% 93.9% 227.8 24.8 20 12.2% 20 1.47% -0.09% 94.4%ASTRAZENECA* 18.9 1.7 18 9.6% 13 1.41% -0.07% 95.3% 56.3 7.8 16 16.2% 11 1.44% 0.00% 100.3% 220.9 43.6 14 24.6% 8 1.43% 0.07% 104.8%DELTA* 18.8 8.0 6 73.7% 1 1.41% 0.48% 151.0% 46.8 15.9 11 51.6% 2 1.20% 0.28% 130.9% 150.6 28.3 17 23.2% 10 0.97% 0.03% 103.6%GLOBAL NAPI 17.5 6.6 8 60.4% 2 1.31% 0.37% 139.4% 47.3 18.3 8 63.3% 1 1.21% 0.35% 140.9% 163.3 40.8 15 33.3% 4 1.06% 0.11% 112.2%NESTLE* 15.6 2.3 15 17.1% 9 1.17% 0.02% 101.8% 48.6 11.7 14 31.6% 5 1.25% 0.15% 113.6% 187.2 25.5 19 15.7% 16 1.21% -0.03% 97.4%SCHERING PLOUGH* 15.1 0.7 21 5.0% 17 1.13% -0.11% 91.3% 47.5 4.4 21 10.2% 17 1.22% -0.06% 95.1% 209.4 28.1 18 15.5% 17 1.35% -0.04% 97.2%JOHNSON E JOHNSON* 14.8 -1.0 22 -6.6% 22 1.11% -0.26% 81.2% 42.7 -0.4 22 -0.9% 22 1.09% -0.19% 85.5% 185.1 20.0 22 12.1% 21 1.20% -0.07% 94.3%HIKMA PLC* 14.7 3.5 10 31.3% 5 1.10% 0.14% 114.1% 42.9 5.6 18 15.1% 12 1.10% -0.01% 99.3% 174.7 33.8 16 24.0% 9 1.13% 0.05% 104.3%Total 67.25% 66.67% 66.70% Total pharma market grew by +15% MTD, +16% YTD & 19% MAT Xx outperform the market in Mar with GR +xx%, +15% YTD & xx% MAT Leading MNCs showed moderate performance with slight decline in MS% (Q1) EGYPT PHARMA Market performance - Walid Saafan 04.10
  3. 3. Top 10 classes Xx presented in xx out of the leading 10 classes, leading position in xx classes. EGYPT PHARMA Market performance - Walid Saafan 04.10
  4. 4. Top 30 products in the market(17% of the total market) Xx has xx products presented in the top 30 products in the market EGYPT PHARMA Market performance - Walid Saafan 04.10
  5. 5. XX market performance High sales momentum in Q1 reaching the xx highest sales of xx Mio EGP and MS% xx% Leading corporate show moderate performance in Q1 EGYPT PHARMA Market performance - Walid Saafan 04.10
  6. 6. Xx leading products performance withinrelevant markets Leadership position in xx (out of 10) leading brands EGYPT PHARMA Market performance - Walid Saafan 04.10
  7. 7. New introductions in the market (> 1 Mio EGP) Xx led the market in terms of new introduction with xx new brands and xx new packs, contributed with an additional sales of xx Mio EGP (xx% of the total introductions in the market). EGYPT PHARMA Market performance - Walid Saafan 04.10
  8. 8. THANK YOUEGYPT PHARMA Market performance - Walid Saafan 04.10

×